Home  >  Products  >  MN1 (meningioma (disrupted in balanced translocation) 1 ) Blocking Peptide (the C terminal of MN1)(100ug)
MN1 (meningioma (disrupted in balanced translocation) 1 ) Blocking Peptide (the C terminal of MN1)(100ug)

MN1 (meningioma (disrupted in balanced translocation) 1 ) Blocking Peptide (the C terminal of MN1)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-MN1 Antibody (ARP63590_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP63590
Size: 100ug
Weight: 136kDa
Gene: The peptide is characterized by mass spectroscopy
Format: Lyophilized powder
Target: Meningioma 1 (MN1) contains two sets of CAG repeats. It is disrupted by a balanced translocation (4;22) in a meningioma, and its inactivation may contribute to meningioma 32 pathogenesis.
Alternative names: MGCR; MGCR1; MGCR1-PEN; dJ353E16.2
See Full Product Listings >